MolMed

{{Expand language|topic=|langcode=it|date=January 2025}}

File:Molmed Logo.png

MOLMED is a biotechnology company founded in 1996 in Milan. It originally operated as contract manufacturing organization and other services for companies developing gene therapy and cell therapy products. In 2000, the company changed its business model and started to develop products of its own.{{cite web|url=http://www.publiem.eu/work/siti_off_line/hsr/companies_molmed.htm |title= MolMed Company Overview |publisher= The San Raffaele Biomedical Science Park}}

In 2001, it signed an agreement with San Raffaele Hospital, that gave MolMed an option to license any gene therapy or cell therapy invention made at the hospital in the fields of cancer and HIV.{{cite news |last1=Taylor |first1=Nick Paul |title=MolMed picks up CAR-T asset from hot Italian research institute |url=https://www.fiercebiotech.com/financials/molmed-picks-up-car-t-asset-from-hot-italian-research-institute |work=FierceBiotech |date=April 16, 2015 |language=en}}

The company was listed on the Milan Stock Exchange in 2008.{{citation needed|date=September 2018}}

In early 2015, MolMed partnered with GlaxoSmithKline related to GSK's acquisition of Strimvelis; MolMed had been involved in the early development of the product.{{cite news |last1=Taylor |first1=Nick Paul |title=GSK dials up value of MolMed gene therapy pact to support growing operation |url=https://www.fiercebiotech.com/biotech/gsk-dials-up-value-molmed-gene-therapy-pact-to-support-growing-operation |work=FierceBiotech |date=September 2, 2016 |language=en}} In March 2020 Fininvest, the reference shareholder with 23.13%, announced its intention to participate in the total takeover bid of the Japanese Agc (Mitsubishi) at the price of 0.518 euros per share, with a 110% premium compared to the price recorded in the session of the previous day (0.24 euro).{{Cite web |title=Molmed, Opa dei giapponesi di Agc. Per Berlusconi 30 milioni di plusvalenza |url=https://www.affaritaliani.it/economia/molmed-opa-dei-giapponesi-di-agc-per-berlusconi-30-milioni-di-plusvalenza-659676.html |access-date=2022-12-08 |website=Affaritaliani.it |language=it}}{{Cite web |date=2020-03-17 |title=Opa giapponese su Molmed, la biotech dei Berlusconi per la lotta ai tumori |url=https://www.repubblica.it/economia/finanza/2020/03/17/news/molmed_agc_opa-251498258/ |access-date=2022-12-08 |website=la Repubblica |language=it}} As of 2020, the company is known as AGC Biologics.{{cite web|url=https://www.agcbio.com/news/molmed-s.p.a-becomes-agc-biologics-s.p.a-following-the-july-acquisition|title=MolMed S.p.A Becomes AGC Biologics S.p.A Following the July Acquisition|date=2020-10-27|access-date=2024-03-26|work=AGC}}